TICKERNERD
Menu
KROSKROSHealthcare · Biotechnology

KROS Stock Forecast: Keros Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 28 Oct 2026
$12
+1.62% on the day

The 7 Wall Street analysts covering Keros Therapeutics, Inc. hold a median 12-month price target of $19 — +63.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 28 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$226.5M
Ticker Nerd rank
72/ 100
Median analyst target
$19
Analysts covering
7
Revenue$0.0−100.0% y/y
Operating income−$30.9M
Net income−$28.7M
Free cash flow−$20.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.8%
1M
+2.9%
YTD
−43.0%
1Y
−23.5%
From 52W high
−46.8%
From 52W low
+17.2%
$10
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KROS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Keros Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
72/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
96
Quality
89
Accruals
81
Volatility
78
Revisions
71
Size
65
Momentum
28
Value
27
Growth
10

Issuance (96): The share count has been shrinking and the company is not leaning on new borrowing.

Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

KROS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KROS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26KROSHigh $25Median $19Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
4 Buy3 Hold0 Sell
Low $16Median $19High $25

The green dot is the last close — the median target sits +63.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Leerink PartnersMaintainsOutperform$30 → $23
4 Aug 2026Wells FargoMaintainsOverweight$20 → $18
5 Mar 2026Wells FargoMaintainsOverweight$23 → $20
5 Mar 2026Wells FargoMaintainsOverweight—
28 Nov 2025B of A SecuritiesMaintainsNeutral—
12 Nov 2025OppenheimerReiteratesOutperform—
11 Nov 2025Wells FargoMaintainsOverweight—
6 Nov 2025WedbushMaintainsNeutral—
8 Aug 2025HC Wainwright & Co.MaintainsBuy—
10 June 2025B of A SecuritiesDowngradeNeutral—
30 May 2025WedbushReiteratesNeutral—
12 May 2025ScotiabankMaintainsSector Outperform—
8 May 2025HC Wainwright & Co.MaintainsBuy—
9 Apr 2025Truist SecuritiesMaintainsBuy—
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
1 Apr 2025WedbushReiteratesNeutral—
27 Feb 2025HC Wainwright & Co.MaintainsBuy—
27 Feb 2025Wells FargoMaintainsOverweight—
21 Jan 2025Cantor FitzgeraldDowngradeNeutral—
17 Jan 2025GuggenheimReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

KROS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

KROS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 28 Oct 2026, Keros Therapeutics, Inc. returned −23.5% against +13.6% for the S&P 500, dividends included.

KROS vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26KROSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

KROS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
2
Fundamentals

Keros Therapeutics, Inc. (KROS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
4.6×

Cheaper than 66% of US stocks

Price / sales
15.3×

Cheaper than 10% of US stocks

Price / book
0.9×

Cheaper than 74% of US stocks

EV / EBITDA
0.2×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−655.8%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−17.2%

Higher than 32% of US stocks

Return on assets
−11.8%

Higher than 25% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Keros Therapeutics, Inc. (KROS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Keros Therapeutics, Inc. has a market value of $226.5M and an enterprise value of −$15.4M.

  • Revenue in the twelve months to 30 June 2026: $15.0M. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$83.2M, a −553.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−3.70.

  • Free cash flow in the twelve months to 30 June 2026: −$48.5M.

  • Shares outstanding: 19.8M.

  • Trailing P/E: 4.6×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Keros Therapeutics, Inc. employs 92 people — $163K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

KROS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KROSKeros Therapeutics, Inc.$226.5M72
CAMPCAMP4 Therapeutics Corp.$229.0M56
EVMNEvommune, Inc.$227.3M11
IKTInhibikase Therapeutics, Inc.$226.0M36
BBOTBridgebio Oncology Therapeutics, Inc.$224.5M6
ELDNEledon Pharmaceuticals, Inc.$224.3M34
SLGLSol-Gel Technologies Ltd.$222.9M52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Keros Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KROS news & analysis

Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage

MarketBeat · 22 Oct 2026neutral

Keros Therapeutics is repositioning its pipeline around rinvatercept, a candidate for skeletal-muscle regeneration being developed for neuromuscular diseases. CEO Jasbir Seehra also said the partnered eleriscept program is advancing through late-stage development under Takeda.

Why it matters — The update describes a shift in Keros’ pipeline focus and gives a status update on its partnered program.

KROS Begins Dosing in Phase II Study With Rinvatercept in DMD

Zacks Investment Research · 29 Sept 2026positive

Keros Therapeutics has begun dosing patients in a Phase II study of rinvatercept for Duchenne muscular dystrophy (DMD). Initial data from the trial are expected in the first half of 2027.

Why it matters — This milestone advances rinvatercept into a new clinical stage and provides KROS watchers with a clear upcoming catalyst in the DMD program.

Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda

GlobeNewsWire · 29 Sept 2026positive

Keros Therapeutics announced it expects to receive a $20 million development milestone payment from partner Takeda under the license agreement for elritercept, following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for myelofibrosis. The trial is a multicenter, double-blind, randomized study comparing elritercept to placebo in patients with myelofibrosis and anemia on concurrent ruxolitinib therapy.

Why it matters — A Keros watcher would care because the milestone payment reflects progress in the elritercept program and provides additional non-dilutive funding for the company.

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

GlobeNewsWire · 28 Sept 2026positive

Keros Therapeutics announced that the first patient has been dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (DMD). The trial is part of the company's efforts to develop novel therapeutics for disorders linked to dysfunctional TGF-ß family protein signaling.

Why it matters — This marks a clinical advancement for Keros' rinvatercept program, moving it into Phase 2 development for DMD, which is a key milestone for the company's pipeline.

Keros Therapeutics Announces $5 Million Share Repurchase Authorization

GlobeNewsWire · 8 Sept 2026positive

Keros Therapeutics announced that its Board of Directors approved a $5 million share repurchase program for the company's common stock, authorizing management to repurchase shares from time to time in the open market or by other means in accordance with securities laws. The authorization follows receipt of a $20 million development milestone payment under the elritercept license agreement with Takeda Pharmaceuticals, triggered by the dosing of the first patient in the ELRiSE MDS clinical trial.

Why it matters — A KROS watcher would care because the repurchase program signals the company has unlocked milestone revenue from its Takeda partnership and is returning capital to shareholders.

FAQ

Frequently asked questions about KROS stock

What is the KROS stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Keros Therapeutics, Inc. have a median 12-month price target of $19, with estimates ranging from $16 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KROS stock a buy right now?

Of the 7 analysts covering Keros Therapeutics, Inc., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Keros Therapeutics, Inc. 72 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KROS?

As at 28 Oct 2026, Keros Therapeutics, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (96 of 100).

Will KROS stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +63.7% from the last close, and Ticker Nerd's factor model ranks Keros Therapeutics, Inc. 72 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KROS stock forecast for 2030?

No analyst covering Keros Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KROS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $25 over the next 12 months.

How has KROS stock performed over the past year?

Keros Therapeutics, Inc. returned -23.5% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Keros Therapeutics, Inc. do?

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins.

What is the latest news on KROS?

The most recent item we track (MarketBeat, 22 Oct 2026): "Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage". Keros Therapeutics is repositioning its pipeline around rinvatercept, a candidate for skeletal-muscle regeneration being developed for neuromuscular diseases. CEO Jasbir Seehra also said the partnered eleriscept program is advancing through late-stage development under Takeda.

Company

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases. The company’s work is built around protein- and pathway-based approaches that target disease mechanisms involved in red blood cell and platelet production, iron regulation, and tissue repair. Keros Therapeutics serves the biotechnology and specialty medicine markets, where it contributes to the development of precision therapies for patients with high unmet medical needs.

CEO Dr. Jasbir S. Seehra Ph.D. · 92 employees · United States · https://www.kerostx.com